Premium
An automated, high‐throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA‐HR/AM)
Author(s) -
Peterman Scott,
Niederkofler Eric E.,
Phillips David A.,
Krastins Bryan,
Kiernan Urban A.,
Tubbs Kemmons A.,
Nedelkov Dobrin,
Prakash Amol,
Vogelsang Maryann S.,
Schoeder Tara,
Couchman Lewis,
Taylor David R.,
Moniz Cajetan F.,
Vadali Gouri,
Byram Gregory,
Lopez Mary F.
Publication year - 2014
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201300300
Subject(s) - chromatography , immunoassay , insulin , mass spectrometry , chemistry , biology , endocrinology , antibody , immunology
The detection and quantification of insulin and its therapeutic analogs is important for medical, sports doping, and forensic applications. Synthetic variants contain slight sequence variations to affect bioavailability. To reduce sample handling bias, a universal extraction method is required for simultaneous extraction of endogenous and variant insulins with subsequent targeted quantification by LC‐MS. A mass spectrometric immunoassay (MSIA), a multiplexed assay for intact insulin and its analogues that couples immunoenrichment with high resolution and accurate mass (HR/AM) spectrometric detection across the clinical range is presented in this report. The assay is sensitive, selective, semi‐automated and can potentially be applied to detect new insulin isoforms allowing their further incorporation into second or third generation assays.